26 November 2013Big Pharma

Teva and Mylan settle Copaxone patent litigation in Europe

Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Teva wins Netherlands Copaxone case

4 October 2013 Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.

UK Appeals Court upholds Teva’s Copaxone patent

1 August 2013 The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.

More on this story

Teva wins Netherlands Copaxone case

4 October 2013 Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.

UK Appeals Court upholds Teva’s Copaxone patent

1 August 2013 The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.

More on this story

Teva wins Netherlands Copaxone case

4 October 2013 Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.

UK Appeals Court upholds Teva’s Copaxone patent

1 August 2013 The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.

More features

'This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards

‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course

Drug approvals up but global innovation declines

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel